Tagged with

Hungary Hungary’s two largest pharma firms, Egis Pharmaceuticals and Gedeon Richter, are stepping up their biosimilars offering; providing the European market with more affordable biologic medicines and bolstering Hungary’s footprint in biologics R&D.   Biosimilars in Europe Over the past decade, over 80 biologic molecules have been launched worldwide. By 2020…

USA The AAM’s Chip Davis examines the roadblocks to greater adoption of biosimilar drugs in the USA, and why they need to be removed to potentially save billions of dollars and increase patient access to lifesaving medications.     In a nutshell: competition brings prices down across the board Biologic drugs…

USA AstraZeneca’s Rick R. Suarez looks at workable solutions to the challenges facing healthcare in the US and why inter-stakeholder collaboration, rather than finger-pointing, is the only way forward.   Discussion and debate related to cost and quality in healthcare has never been more pronounced or more contentious, whether focusing on…

Hungary Like many of its European counterparts, Hungary is suffering from medicine shortages. Vaccines, vitamins, and orphan drugs are some of the most affected areas and oncology patients are now also at risk.   An Increasing Burden Over 14,000 types of pharmaceuticals are unavailable in Hungarian pharmacies, which is placing an…

Europe Awareness is growing of the dangers of healthcare-associated infections (HAIs) in Europe, and conversations are beginning to taking place around how to leverage data to combat these infections and antimicrobial resistance (AMR). A panel of experts from diverse backgrounds at the European Health Forum Gastein put their heads together to…

Hungary Hungarian patients currently experience longer wait times and more limited access to subsidised innovative medicines than their neighbours in Bulgaria and Slovakia.leading some organisations to urge the government to increase funding and shorten approval times.   According to the Hungarian Association of Innovative Pharma Manufacturers, since 2016 only 48 new…

4+7 China’s roll-out of a 25-province expansion to the 4+7 pilot procurement scheme has seen pharma companies scrambling to cut prices for their drugs even further in the latest bidding war.   Pharma companies in China are facing yet another intense race to the bottom on pricing. On the 24th of…

Puerto Rico David Fuster, plant manager of the Dorado factory of Chinese pharma outfit PuraCap, shares the company’s strategy behind the investment in Puerto Rico and how the PuraCap Caribe is leveraging technologies at the facility for new product development. He underlines the importance of Puerto Rico as a manufacturing location for…

UAE The mission of the Swiss Business Council (SBC) is to provide a forum for Swiss executives and those with Swiss business interested to identify, discuss and pursue common interests regarding their activities. Peter Harradine, president of SBC Dubai & Northern Emirates discusses FDI inflows into the UAE, the strategic significance…

Puerto Rico Iliette Frontera, VP Operations of Boston Scientific in Puerto Rico, shares the significance of the Dorado site within the group’s global supply chain, her four priorities to ensure sustainable growth, lessons learned from Hurricane Maria, and the importance of gender equality.   You have to be extremely agile and you…

Sweden Johan Folkunger, CEO of Philips Sweden, discusses the transformation from a conglomerate into a healthtech company focused on health and wellbeing, the unique partnership with the Karolinska University Hospital including the establishment of a global research hub in Sweden, and the effort to move healthcare away from the hospitals. Folkunger…

Puerto Rico Dr Rafael Rodríguez Mercado, Secretary of Health for Puerto Rico, explains the priorities his administration has put in place, the impact of Hurricane Maria on the Puerto Rican healthcare system, and the next crucial rebuilding steps.   The next challenge that we have will be regarding accountability, in other words,…